440 related articles for article (PubMed ID: 27392859)
21. Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease.
Kester MI; Teunissen CE; Crimmins DL; Herries EM; Ladenson JH; Scheltens P; van der Flier WM; Morris JC; Holtzman DM; Fagan AM
JAMA Neurol; 2015 Nov; 72(11):1275-80. PubMed ID: 26366630
[TBL] [Abstract][Full Text] [Related]
22. Increased levels of the synaptic proteins PSD-95, SNAP-25, and neurogranin in the cerebrospinal fluid of patients with Alzheimer's disease.
Kivisäkk P; Carlyle BC; Sweeney T; Quinn JP; Ramirez CE; Trombetta BA; Mendes M; Brock M; Rubel C; Czerkowicz J; Graham D; Arnold SE
Alzheimers Res Ther; 2022 Apr; 14(1):58. PubMed ID: 35461266
[TBL] [Abstract][Full Text] [Related]
23. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
24. Plasma neuregulin 1 as a synaptic biomarker in Alzheimer's disease: a discovery cohort study.
Vrillon A; Mouton-Liger F; Martinet M; Cognat E; Hourregue C; Dumurgier J; Bouaziz-Amar E; Brinkmalm A; Blennow K; Zetterberg H; Hugon J; Paquet C
Alzheimers Res Ther; 2022 May; 14(1):71. PubMed ID: 35606871
[TBL] [Abstract][Full Text] [Related]
25. Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease.
Zetterberg H; Andreasson U; Hansson O; Wu G; Sankaranarayanan S; Andersson ME; Buchhave P; Londos E; Umek RM; Minthon L; Simon AJ; Blennow K
Arch Neurol; 2008 Aug; 65(8):1102-7. PubMed ID: 18695061
[TBL] [Abstract][Full Text] [Related]
26. Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression.
Siafarikas N; Kirsebom BE; Srivastava DP; Eriksson CM; Auning E; Hessen E; Selbaek G; Blennow K; Aarsland D; Fladby T
Sci Rep; 2021 Oct; 11(1):20375. PubMed ID: 34645914
[TBL] [Abstract][Full Text] [Related]
27. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
28. Increased CSF-BACE1 activity associated with decreased hippocampus volume in Alzheimer's disease.
Ewers M; Cheng X; Zhong Z; Nural HF; Walsh C; Meindl T; Teipel SJ; Buerger K; He P; Shen Y; Hampel H
J Alzheimers Dis; 2011; 25(2):373-81. PubMed ID: 21460439
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal Fluid Neurogranin as a Biomarker of Neurodegenerative Diseases: A Cross-Sectional Study.
Lista S; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Dos Santos AM; Epelbaum S; Lamari F; Dubois B; Nisticò R; Floris R; Garaci F; Hampel H;
J Alzheimers Dis; 2017; 59(4):1327-1334. PubMed ID: 28731449
[TBL] [Abstract][Full Text] [Related]
30. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
Parnetti L; Chiasserini D; Eusebi P; Giannandrea D; Bellomo G; De Carlo C; Padiglioni C; Mastrocola S; Lisetti V; Calabresi P
J Alzheimers Dis; 2012; 29(1):229-38. PubMed ID: 22232006
[TBL] [Abstract][Full Text] [Related]
31. Cerebrospinal Fluid Concentration of Neurogranin in Hip Fracture Patients with Delirium.
Halaas NB; Zetterberg H; Idland AV; Knapskog AB; Watne LO; Blennow K
J Alzheimers Dis; 2021; 81(2):667-677. PubMed ID: 33814433
[TBL] [Abstract][Full Text] [Related]
32. Macrophage Migration Inhibitory Factor is Associated with Biomarkers of Alzheimer's Disease Pathology and Predicts Cognitive Decline in Mild Cognitive Impairment and Mild Dementia.
Oikonomidi A; Tautvydaitė D; Gholamrezaee MM; Henry H; Bacher M; Popp J
J Alzheimers Dis; 2017; 60(1):273-281. PubMed ID: 28826184
[TBL] [Abstract][Full Text] [Related]
33. Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics.
Tijms BM; Gobom J; Reus L; Jansen I; Hong S; Dobricic V; Kilpert F; Ten Kate M; Barkhof F; Tsolaki M; Verhey FRJ; Popp J; Martinez-Lage P; Vandenberghe R; Lleó A; Molinuevo JL; Engelborghs S; Bertram L; Lovestone S; Streffer J; Vos S; Bos I; ; Blennow K; Scheltens P; Teunissen CE; Zetterberg H; Visser PJ
Brain; 2020 Dec; 143(12):3776-3792. PubMed ID: 33439986
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal changes of CSF biomarkers in Alzheimer's disease.
Seppälä TT; Koivisto AM; Hartikainen P; Helisalmi S; Soininen H; Herukka SK
J Alzheimers Dis; 2011; 25(4):583-94. PubMed ID: 21460434
[TBL] [Abstract][Full Text] [Related]
35. T1rho MRI and CSF biomarkers in diagnosis of Alzheimer's disease.
Haris M; Yadav SK; Rizwan A; Singh A; Cai K; Kaura D; Wang E; Davatzikos C; Trojanowski JQ; Melhem ER; Marincola FM; Borthakur A
Neuroimage Clin; 2015; 7():598-604. PubMed ID: 25844314
[TBL] [Abstract][Full Text] [Related]
36. Full-length and C-terminal neurogranin in Alzheimer's disease cerebrospinal fluid analyzed by novel ultrasensitive immunoassays.
Öhrfelt A; Dumurgier J; Zetterberg H; Vrillon A; Ashton NJ; Kvartsberg H; Bouaziz-Amar E; Hugon J; Paquet C; Blennow K
Alzheimers Res Ther; 2020 Dec; 12(1):168. PubMed ID: 33353563
[TBL] [Abstract][Full Text] [Related]
37. Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: Aβ
Hampel H; Toschi N; Baldacci F; Zetterberg H; Blennow K; Kilimann I; Teipel SJ; Cavedo E; Melo Dos Santos A; Epelbaum S; Lamari F; Genthon R; Dubois B; Floris R; Garaci F; Lista S;
Alzheimers Dement; 2018 Apr; 14(4):492-501. PubMed ID: 29328927
[TBL] [Abstract][Full Text] [Related]
38. Interactions between amyloid-β and tau in cerebrospinal fluid of people with mild cognitive impairment and Alzheimer's disease.
Kristofikova Z; Ricny J; Kolarova M; Vyhnalek M; Hort J; Laczo J; Sirova J; Ripova D
J Alzheimers Dis; 2014; 42 Suppl 3():S91-8. PubMed ID: 24670397
[TBL] [Abstract][Full Text] [Related]
39. Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease.
Rosén C; Andreasson U; Mattsson N; Marcusson J; Minthon L; Andreasen N; Blennow K; Zetterberg H
Neuromolecular Med; 2012 Mar; 14(1):65-73. PubMed ID: 22350541
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease.
Niemantsverdriet E; Goossens J; Struyfs H; Martin JJ; Goeman J; De Deyn PP; Vanderstichele H; Engelborghs S
J Alzheimers Dis; 2016; 51(1):97-106. PubMed ID: 26836187
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
